Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain

BACKGROUND: A recent randomized‐withdrawal, active‐ and placebo‐controlled, double‐blind phase 3 study showed that tapentadol prolonged release (PR) was effective and well tolerated for managing moderate to severe, chronic malignant tumour‐related pain in patients who were opioid naive or dissatisfi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Pain
Egile Nagusiak: Kress, H.G., Koch, E.D., Kosturski, H., Steup, A., Karcher, K., Dogan, C., Etropolski, M., Eerdekens, M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2016
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5071659/
https://ncbi.nlm.nih.gov/pubmed/27062079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejp.875
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak